BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Johnson & Johnson (JNJ) Diabetes Pill May Have Heart Risks, FDA Staff Says


1/8/2013 8:27:26 AM

Johnson & Johnson (JNJ)’s experimental diabetes pill may carry heart risks, U.S. regulators said in a review that threatens to delay the company’s first-to-market status among a new family of medicines. Studies for the drug canagliflozin, which expels sugar in the urine after it’s filtered from blood by the kidneys, showed a potentially higher risk for heart events in the first 30 days compared with a placebo, Food and Drug Administration staff said today in a report. An FDA advisory panel is set to meet Jan. 10 to make recommendations to the agency on the drug. The once-a-day pill is J&J’s effort to be the first to market with a new class of diabetes treatments known as SGLT2 inhibitors aimed at cutting side effects from current drugs. The drugs are also being developed by Eli Lilly & Co. (LLY), Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co. (BMY) and AstraZeneca Plc. (AZN). A delay to further assess risk “could erase its first mover advantage,” Lawrence Biegelsen, an analyst with Wells Fargo Securities in New York, wrote in a note to clients yesterday. “A first-to-market position is an important marketing advantage in this arena.” J&J, based in New Brunswick, New Jersey, fell less than 1 percent to $71.37 at 9:34 a.m. New York time. Canagliflozin, may generate $446 million in sales in 2016 if approved, according to the average estimate of three analysts surveyed by Bloomberg. The drugmaker has proposed marketing canagliflozin under the name Invokana for adults with Type 2 diabetes. It worked as well against diabetes in clinical trials as Januvia, Merck & Co.’s second-best selling drug, and a generic treatment called glimepiride, FDA staff said.

Read at Bloomberg

Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES